Incyte Corporation · NASDAQ:INCY
Incyte — Technical Presentation (March 2026)
13 slides from Incyte's technical presentation, March 2026
Slide 1: Povorcitinib in Moderate to Severe HS: 54-Week Efficacy and Safety Results
Presentation 80034 Povorcitinib in Patients With Moderate to Severe Hidradenitis Suppurativa: 54-Week Efficacy and Safety Results From the STOP-HS1 & STOP-HS2 Phase 3 Studies Martina L. Porter, MD,1 Antonio Martorell, MD, PhD,2 Christopher J. Sayed, MD,3 Falk G. Bechara, MD,4 Hadar Lev-Tov, MD, MAS,
Slide 2: Presenting Author Disclosures
Presenting Author Disclosures ● Martina L. Porter has served as a consultant for AbbVie, Almirall, Arcutis, Aristea Therapeutics, Avalo Therapeutics, Eli Lilly and Company, FIDE, Incyte, Janssen, Merck, MoonLake Immunotherapeutics, Navigator Biosciences, Novartis, Pfizer, Prometheus, Sanofi, Sonoma
Slide 3: Introduction
Introduction ● HS is a chronic, recurrent inflammatory condition that involves multiple immune pathways and cytokines signaling through JAK11,2 ● Povorcitinib is an oral, highly selective JAK1 inhibitor in clinical development for inflammatory conditions, including HS3,4 ● In the phase 3 STOP-HS1/ST
Slide 4: STOP-HS Study Design
STOP-HS Study Design NCT05620823 and NCT05620836 ● Selective Treatment of Oral Povorcitinib STOP-HS1 (N=608) and STOP-HS2 (N=619) in Hidradenitis Suppurativa Study 1 and Screening Placebo-Controlled Period Extension Period Study 2 are identical in design (up to 28 days) (12 weeks) (42 weeks) – N=122
Slide 5: Demographics and Baseline Clinical Characteristics
Demographics and Baseline Clinical Characteristics Characteristic Overall (N=1227) STOP-HS1 (n=608) STOP-HS2 (n=619) Age, median (range), y 37.0 (18–77) 37.0 (18–77) 37.0 (18–70) Female, n (%) 770 (62.8) 403 (66.3) 367 (59.3) Race, n (%): White / Black 915 (74.6) / 174 (14.2) 438 (72.0) / 98 (16.1)
Slide 6: HiSCR50 Responses Improved Through Week 54
HiSCR50 Responses Improved Through Week 54 ● The HiSCR50 primary endpoint at Week 12 was statistically significant vs placebo for both povorcitinib doses in both studies, with continuous improvement through Week 54 Placebo 45 mg 75 mg Placebo→45 mg Placebo→75 mg STOP-HS1 STOP-HS2 PC (NRI) EXT (OC) P
Slide 7: Povorcitinib Achieved High-Threshold HiSCR Responses
Povorcitinib Achieved High-Threshold HiSCR Responses ● Increase in high-threshold HiSCR responses was observed, with up to 29.0% of povorcitinib- treated patients achieving HiSCR100 at Week 54 HiSCR75 HiSCR90 HiSCR100 STOP-HS1 STOP-HS2 Week 12 (NRI) Week 54 (OC) Week 12 (NRI) Week 54 (OC) Placebo Po
Slide 8: Povorcitinib Consistently Decreased Lesion Counts at Week 54
Povorcitinib Consistently Decreased Lesion Counts at Week 54 ● Across both studies, full clearance of inflammatory lesions (ANdT=0) was achieved in 16.1%–20.2% of patients, with improvements observed in all lesion types through Week 54 45 mg 75 mg Inflammatory Nodule Abscess Draining Tunnel STOP-HS1
Slide 9: Patient-Reported Outcomes at Week 54
Patient-Reported Outcomes at Week 54 ● A high percentage of patients achieved clinically meaningful improvements in several measures of QoL 45 mg 75 mg ≥3-Point Decrease in ≥4-Point Improvement ≥4-Point Decrease in ≥21-Point Decrease in Skin Pain NRS† in FACIT-F‡ DLQI§ HiSQoL Total Score# 50 46.8 60
Slide 10: Safety Summary: Povorcitinib-Treated (Up to Week 54)
Safety Summary: Povorcitinib-Treated (Up to Week 54) STOP-HS1 STOP-HS2 Povorcitinib 45 mg Povorcitinib 75 mg Povorcitinib 45 mg Povorcitinib 75 mg Patients, n (%) n=296† n=295‡ n=298† n=299‡ Any TEAE 232 (78.4) 246 (83.4) 227 (76.2) 242 (80.9) Treatment-related TEAE 116 (39.2) 141 (47.8) 110 (36.9)
Slide 11: TEAEs Associated With Laboratory Parameters
TEAEs Associated With Laboratory Parameters: PC Period and Povorcitinib-Treated (Up to Week 54) PC Period, POOLED (up to 12 weeks) PC+EXT Periods, POOLED (up to 54 weeks) Placebo Povorcitinib 45 mg Povorcitinib 75 mg Povorcitinib 45 mg Povorcitinib 75 mg Patients, n (%) n=405 n=412 n=409 n=594† n=59
Slide 12: Conclusions
Conclusions ● Povorcitinib demonstrated substantial clinical efficacy in moderate to severe HS through Week 54 – Patients treated with povorcitinib achieved high levels of response across HiSCR thresholds at Week 54, with up to 29% achieving HiSCR100 – Consistent resolution of inflammatory nodules (
Slide 13: Thank You For Your Attention
Thank You For Your Attention ● The authors wish to thank the patients and their families, the investigators, and the site personnel who participated in this study ● They also thank Chenwei Tian, PhD, Jennifer Kelley, PhD, and Kurt Brown, MD, of Incyte Corporation (Wilmington, DE, USA) for their cont